ClinicalTrials.gg
Active, not recruitingNCT02178410Updated Nov 13, 2026

VITAL Rhythm Study

A Phase 3 interventional study of Vitamin D3 and Omega-3 fatty acids (fish oil) in Cardiovascular Disease, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Brigham and Women's Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Oct 2012, registered Jun 2014).
Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25,119
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The VITamin D and OmegA-3 TriaL (VITAL) is an ongoing randomized clinical trial of 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in individuals who do not have a prior history of these illnesses. The purpose of this ancillary study is to ascertain and adjudicate atrial fibrillation (AF) outcomes for the primary aim of testing whether omega-3 fatty acid and/or vitamin D supplementation influence atrial fibrillation risk in the general population. We also plan to examine how these agents might impact the development of AF subtypes (persistent versus paroxysmal), intermediate phenotypes for heart rhythm disorders (electrocardiographic parameters), as well as explore effects on arrhythmic death and whether baseline blood levels and/or race modify treatment effects.

Read the detailed description

Atrial fibrillation and sudden cardiac death assessments, as well as blood analyses, will be conducted on the entire VITAL Study population, and ECG analyses will be limited to the Clinical and Translational Science Center (CTSC) sub-cohort of 1,054 VITAL participants who live near the Boston area and agree to participate in a series of ancillary studies in addition to the main trial.

Investigators will ascertain atrial fibrillation events utilizing self-report of physician diagnoses of atrial fibrillation received on annual questionnaires from study participants supplemented by outpatient and hospital visits for AF identified through Centers for Medicare and Medicaid Services (CMS) data linkage. Investigators will also ascertain additional information regarding atrial fibrillation diagnosis from supplementary questionnaires, and seek consent to review all inpatient and outpatient hospital records pertaining to atrial fibrillation diagnosis and evaluation. Atrial fibrillation events will be confirmed by an endpoint committee composed of cardiologists, which will also make a determination on atrial fibrillation subtype and pattern. Questionnaires that inquire about recurrent atrial fibrillation events, pattern of AF, latest medical record evaluation and treatments for AF will be sent to participants with confirmed atrial fibrillation. Medical records will be requested and reviewed an endpoint committee to determine atrial fibrillation subtype and progression. An intention-to-treat analysis examining the 5-year treatment effects of omega-3 fatty acids and vitamin D on incident atrial fibrillation, as well as subtypes at the time of diagnosis will be performed to address the primary aims. We will repeat these analyses at the end of extended follow-up to assess cumulative and post-treatment effects of omega-3 fatty acids and vitamin D and AF subtypes two years after diagnosis.

Electrocardiograms will be obtained at baseline and again after two years of treatment and follow-up among a sub-cohort of 1,054 patients being enrolled in VITAL at the CTSC. Investigators will utilize these ECG data to evaluate whether treatment with omega-3 fatty acids and vitamin D3 have significant effects on ECG measures. The ECGs will also be utilized to estimate the prevalence of asymptomatic persistent atrial fibrillation in our population not detected by our atrial fibrillation surveillance methods.

Investigators will examine baseline blood samples for participants with confirmed atrial fibrillation for the purpose of exploring whether the effect of vitamin D3 or fish oil supplementation on atrial fibrillation risk varies by the baseline blood levels of these nutrients.

Investigators will also seek additional information necessary to classify deaths as sudden or arrhythmic in origin, and cardiac deaths will be reviewed by an endpoint committee of cardiologists. Once these results have been compiled investigators will explore whether omega-3 fatty acids and/or vitamin D might have an effect on sudden and/or arrhythmic cardiac death.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Atrial Fibrillation
  • Vitamin D3
  • Omega-3 fatty acids
  • Fish oil
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 25,119 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

To be eligible this ancillary study participants must be enrolled in the Vitamin D and Omega-3 Trial (VITAL; National Clinical Trial (NCT) 01169259) and meet the following criteria:

Inclusion criteria

Inclusion Criteria:

- physician diagnosis of atrial fibrillation after randomization

and/or

- cardiovascular death

Exclusion criteria

Exclusion Criteria:

- physician diagnosis of atrial fibrillation prior to randomization

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25,119 participants (actual)

Study arms

  • Active comparator
    Vitamin D + fish oil

    Dietary Supplement: Vitamin D3 · Drug: Omega-3 fatty acids (fish oil)

  • Active comparator
    Vitamin D + fish oil placebo

    Dietary Supplement: Vitamin D3 · Dietary Supplement: Fish oil placebo

  • Active comparator
    Vitamin D placebo + fish oil

    Drug: Omega-3 fatty acids (fish oil) · Dietary Supplement: Vitamin D3 placebo

  • Placebo comparator
    Vitamin D placebo + fish oil placebo

    Dietary Supplement: Fish oil placebo · Dietary Supplement: Vitamin D3 placebo

Interventions

  • Dietary supplementCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vitamin D3 (cholecalciferol), 2000 IU per day.

    Also known as: cholecalciferol

  • DrugOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

  • Dietary supplementFish oil placebo

    Fish oil placebo

  • Dietary supplementVitamin D3 placebo

    Vitamin D3 placebo

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation

    To assess whether omega-3 fatty acids (Omacor® 840 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) or vitamin D3 supplementation influences risk of atrial fibrillation in a general population of men and women without prior cardiovascular disease.

    Time frame: 7 years

Secondary outcomes

  1. Atrial Fibrillation

    To examine the short and long-term impacts of vitamin D3 and EPA+DHA supplementation on the development of AF subtypes.

    Time frame: 7 years

  2. Arrhythmic endpoints

    To examine the effect of vitamin D3 or EPA+DHA supplementation on electrocardiographic parameters to further understand mechanisms underlying associations with arrhythmic endpoints.

    Time frame: 5 years

Other outcomes

  1. Sudden Cardiac Death

    To explore effects of arrhythmic death and whether baseline blood levels and/or race modify treatment effects.

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Publications

  • Qian F, Tintle N, Jensen PN, Lemaitre RN, Imamura F, Feldreich TR, Nomura SO, Guan W, Laguzzi F, Kim E, Virtanen JK, Steur M, Bork CS, Hirakawa Y, O'Donoghue ML, Sala-Vila A, Ardisson Korat AV, Sun Q, Rimm EB, Psaty BM, Heckbert SR, Forouhi NG, Wareham NJ, Marklund M, Riserus U, Lind L, Arnlov J, Garg P, Tsai MY, Pankow J, Misialek JR, Gigante B, Leander K, Pester JA, Albert CM, Kavousi M, Ikram A, Voortman T, Schmidt EB, Ninomiya T, Morrow DA, Bayes-Genis A, O'Keefe JH, Ong KL, Wu JHY, Mozaffarian D, Harris WS, Siscovick DS; Fatty Acids and Outcomes Research Consortium (FORCE). Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation. J Am Coll Cardiol. 2023 Jul 25;82(4):336-349. doi: 10.1016/j.jacc.2023.05.024. PubMed 37468189 ↗
  • Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021 Dec 21;144(25):1981-1990. doi: 10.1161/CIRCULATIONAHA.121.055654. Epub 2021 Oct 6. PubMed 34612056 ↗
  • Middeldorp ME, Sandhu RK, Mao J, Gencer B, Danik JS, Moorthy V, Cook NR, Albert CM. Risk Factors for the Development of New-Onset Persistent Atrial Fibrillation: Subanalysis of the VITAL Study. Circ Arrhythm Electrophysiol. 2023 Dec;16(12):651-662. doi: 10.1161/CIRCEP.123.012334. Epub 2023 Nov 29. PubMed 38018439 ↗
  • Siddiqi HK, Vinayagamoorthy M, Gencer B, Ng C, Pester J, Cook NR, Lee IM, Buring J, Manson JE, Albert CM. Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study. JAMA Cardiol. 2022 Oct 1;7(10):1027-1035. doi: 10.1001/jamacardio.2022.2825. PubMed 36044209 ↗
  • Albert CM, Cook NR, Pester J, Moorthy MV, Ridge C, Danik JS, Gencer B, Siddiqi HK, Ng C, Gibson H, Mora S, Buring JE, Manson JE. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2021 Mar 16;325(11):1061-1073. doi: 10.1001/jama.2021.1489. PubMed 33724323 ↗
  • Tikkanen JT, Soliman EZ, Pester J, Danik JS, Gomelskya N, Copeland T, Lee IM, Buring JE, Manson JE, Cook NR, Albert CM. A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles. Sci Rep. 2023 Jul 15;13(1):11454. doi: 10.1038/s41598-023-38344-x. PubMed 37454148 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2012 (actual). Primary completion is estimated for Oct 2027, 180 months after the start.

Of 40 non-industry phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 180 months is above that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 30, 2014
StartActual
Oct 2012
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 13, 2026
Study completion
Oct 2026→Oct 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02178410
Responsible party
Christine M. Albert, MD, MPH (Principle Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Jun 30, 2014
Start date
Oct 2012
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Christine M. Albert, M.D., M.P.H.
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cholecalciferol · Omega-3 fatty acid

Start the discussion